Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3573 | VLA2001 Wiki | 0.71 |
| drug1916 | MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg Wiki | 0.71 |
| drug1818 | Licensed seasonal influenza vaccine Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2570 | Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine Wiki | 0.71 |
| drug2924 | SARS-CoV-2 rS/Matrix M1-Adjuvant Wiki | 0.71 |
| drug1917 | MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg Wiki | 0.71 |
| drug1643 | Inactivated SARS-CoV-2 vaccine (Vero cell) Wiki | 0.71 |
| drug1915 | MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg Wiki | 0.71 |
| drug2490 | Placebo Wiki | 0.18 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
This is a randomized, double blind, placebo parallel-controlled phase III clinical trial to evaluate the efficacy, immunogenicity and safety of the inactivated SARS-CoV-2 Vaccine (Vero cell) in Argentine healthy population aged between 18 and 85 years old.
Description: All confirmed COVID -19 cases 14 days after the full course of vaccination among healthy population aged between 18 and 85 years old.
Measure: Incidence of COVID-19 cases after two-doses of vaccination Time: 14 days after the full course of vaccinationDescription: The protective level of Anti-SARS-CoV-2 NtAbs
Measure: Anti-SARS-CoV-2 neutralizing antobody (NtAb) (immunological surrogate endpoint) Time: 14 days after 2-dose of immunization.This study is being conducted to look at the safety and immune response (how the immune system of the human body reacts) to a vaccine for SARS-CoV-2 (the virus responsible for COVID-19 infection) when administered as an intramuscular injection (an injection directly into the muscle) to the upper arm of healthy participants, on two occasions at least 28 days apart.
Description: - the frequency of solicited local reactogenicity adverse events (AEs)
Measure: Frequency of Solicited local reactogenicity adverse events (AEs) Time: 7 days following each vaccination (at Days 1 and 29)Description: - the frequency of solicited systemic reactogenicity AEs
Measure: Frequency of Solicited systemic reactogenicity adverse events (AEs) Time: 7 days following each vaccination (at Days 1 and 29)Description: - the grading of solicited local reactogenicity adverse events (AEs)
Measure: Grading of Solicited local reactogenicity adverse events (AEs) Time: 7 days following each vaccination (at Days 1 and 29)Description: - the grading of solicited systemic reactogenicity AEs
Measure: Grading of Solicited systemic reactogenicity adverse events (AEs) Time: 7 days following each vaccination (at Days 1 and 29)Description: - the frequency, duration, intensity and relationship to vaccination of unsolicited local adverse events (AEs)
Measure: Unsolicited adverse events (AEs) Time: 28 days following each vaccination (at Days 1 and 29)Description: - the frequency, duration, intensity and relationship to vaccination of Serious adverse events (SAEs), Medically attended adverse events (MAAEs) and any Adverse events (AEs) leading to study withdrawal at any time during the study (including decision by the Principal Investigator [PI] not to proceed with the second dose) at any time during the study
Measure: Serious adverse events (SAEs), Medically attended adverse events (MAAEs) and any Adverse events (AEs) leading to study withdrawal at any time during the study Time: through study completion (394 days)Description: - Geometric mean titre (GMT) of the serum antibody response compared to placebo
Measure: Geometric Mean Titer (GMT) of the serum antibody response Time: 28 days following each vaccination (Days 29 and 57)Description: GMT of the serum NAb titres to SARS-CoV-2 virus compared to placebo
Measure: Geometric Mean Titer (GMT) of the serum neutralizing antibody (NAb) response to SARS-CoV-2 virus Time: 28 days following each vaccination (Days 29 and 57)Description: GMT of the serum antibody response compared to placebo
Measure: Total serum antibody immune responses Time: through study completion (394 days)Description: proportion of participants with greater than or equal to 4 fold increase in titre above baseline compared to placebo.
Measure: proportion of participants with ≥ 4 fold increase in titer above baseline Time: through study completion (394 days)Description: GMT of the serum neutralizing antibody (NAb) immune responses compared to placebo
Measure: GMT of the serum neutralizing antibody (NAb) titres Time: through study completion (394 days)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports